Top-Rated StocksTop-RatedNASDAQ:ARGX argenx (ARGX) Stock Forecast, Price & News $388.70 -3.66 (-0.93%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$386.69▼$396.2150-Day Range$356.85▼$422.5852-Week Range$304.14▼$423.99Volume252,684 shsAverage Volume234,963 shsMarket Capitalization$21.64 billionP/E RatioN/ADividend YieldN/APrice Target$454.24 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media argenx MarketRank™ ForecastAnalyst RatingModerate Buy2.94 Rating ScoreUpside/Downside16.8% Upside$455.67 Price TargetShort InterestBearish1.98% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.33) to ($4.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector673rd out of 1,006 stocksBiological Products, Except Diagnostic Industry102nd out of 167 stocks 3.5 Analyst's Opinion Consensus Ratingargenx has received a consensus rating of Buy. The company's average rating score is 2.95, and is based on 18 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $455.67, argenx has a forecasted upside of 16.8% from its current price of $390.01.Amount of Analyst Coverageargenx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.98% of the outstanding shares of argenx have been sold short.Short Interest Ratio / Days to Coverargenx has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in argenx has recently increased by 22.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yieldargenx does not currently pay a dividend.Dividend Growthargenx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARGX. Previous Next 3.2 News and Social Media Coverage News Sentimentargenx has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for argenx this week, compared to 4 articles on an average week.Search Interest10 people have searched for ARGX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added argenx to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, argenx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.43% of the stock of argenx is held by insiders.Percentage Held by Institutions57.29% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for argenx are expected to grow in the coming year, from ($6.33) to ($4.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of argenx is -41.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of argenx is -41.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratioargenx has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About argenx (NASDAQ:ARGX) Stockargenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.Read More Receive ARGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARGX Stock News HeadlinesMay 31, 2023 | americanbankingnews.comargenx (NASDAQ:ARGX) Receives New Coverage from Analysts at UBS GroupMay 31, 2023 | americanbankingnews.comargenx SE (NASDAQ:ARGX) Receives $454.24 Average Target Price from AnalystsMay 31, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 29, 2023 | americanbankingnews.comargenx SE (NASDAQ:ARGX) Short Interest Up 23.0% in MayMay 28, 2023 | americanbankingnews.comContrasting argenx (NASDAQ:ARGX) and Fate Therapeutics (NASDAQ:FATE)May 22, 2023 | msn.comChart of the Day: Argenx - Great BiotechMay 20, 2023 | seekingalpha.comargenx: Q1 Earnings, High Stakes Biotech Play - Soaring Success Or Icarus' FallMay 18, 2023 | ca.finance.yahoo.comargenx SE (ARGX) Stock Price, News, Quote & History - Yahoo FinanceMay 31, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 18, 2023 | americanbankingnews.comargenx (NASDAQ:ARGX) Sees Strong Trading VolumeMay 16, 2023 | americanbankingnews.comargenx SE (NASDAQ:ARGX) Short Interest UpdateMay 12, 2023 | finance.yahoo.comHers’s Why Baron Opportunity Fund Trimmed argenx SE (ARGX)May 11, 2023 | benzinga.comThis Is What Whales Are Betting On argenxMay 9, 2023 | americanbankingnews.comargenx SE Expected to Earn Q1 2025 Earnings of ($1.15) Per Share (NASDAQ:ARGX)May 9, 2023 | americanbankingnews.comFY2026 EPS Estimates for argenx SE (NASDAQ:ARGX) Cut by HC WainwrightMay 8, 2023 | americanbankingnews.comBrokerages Set argenx SE (NASDAQ:ARGX) Target Price at $452.94May 8, 2023 | americanbankingnews.comargenx (NASDAQ:ARGX) Price Target Raised to $440.00May 6, 2023 | seekingalpha.comargenx SE 2023 Q1 - Results - Earnings Call PresentationMay 6, 2023 | americanbankingnews.comBank of America Boosts argenx (NASDAQ:ARGX) Price Target to $446.00May 6, 2023 | americanbankingnews.comargenx (NASDAQ:ARGX) Given New $445.00 Price Target at JMP SecuritiesMay 5, 2023 | americanbankingnews.comargenx (NASDAQ:ARGX) Price Target Increased to $494.00 by Analysts at HC WainwrightMay 2, 2023 | finance.yahoo.comargenx to Present at BofA Securities 2023 Health Care ConferenceMay 1, 2023 | seekingalpha.comargenx (ARGX) Investor Presentation - SlideshowApril 27, 2023 | americanbankingnews.comargenx (NASDAQ:ARGX) Now Covered by CitigroupApril 27, 2023 | finance.yahoo.comargenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023April 24, 2023 | americanbankingnews.comargenx (NASDAQ:ARGX) Given "Outperform" Rating at WedbushApril 21, 2023 | seekingalpha.comargenx: Exciting Genmab Partnership, All Eyes On Q1 Earnings And CIDP ReadoutSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARGX Company Calendar Last Earnings5/04/2023Today5/31/2023Next Earnings (Estimated)7/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARGX CUSIPN/A CIK1697862 Webwww.argenx.com Phone(176) 303-0488FaxN/AEmployees650Year FoundedN/APrice Target and Rating Average Stock Price Forecast$455.67 High Stock Price Forecast$494.00 Low Stock Price Forecast$425.00 Forecasted Upside/Downside+16.7%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($9.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-709,590,000.00 Net Margins-79.45% Pretax Margin-89.41% Return on Equity-35.36% Return on Assets-32.04% Debt Debt-to-Equity RatioN/A Current Ratio9.18 Quick Ratio8.42 Sales & Book Value Annual Sales$445.27 million Price / Sales48.66 Cash FlowN/A Price / Cash FlowN/A Book Value$50.79 per share Price / Book7.66Miscellaneous Outstanding Shares55,680,000Free Float54,325,000Market Cap$21.67 billion OptionableOptionable Beta0.75 Key ExecutivesTim van HauwermeirenChief Executive Officer & Executive DirectorKaren MasseyChief Operating OfficerKarl GubitzChief Financial OfficerLuc TruyenChief Medical OfficerPeter UlrichtsChief Scientific OfficerKey CompetitorsBioNTechNASDAQ:BNTXBio-TechneNASDAQ:TECHQiagenNYSE:QGENRepligenNASDAQ:RGENNeurocrine BiosciencesNASDAQ:NBIXView All CompetitorsInstitutional OwnershipProShare Advisors LLCSold 512 shares on 5/26/2023Ownership: 0.004%Ameriprise Financial Inc.Sold 25,609 shares on 5/22/2023Ownership: 0.002%JPMorgan Chase & Co.Bought 39,800 shares on 5/18/2023Ownership: 0.000%Thrivent Financial for LutheransBought 1,044 shares on 5/17/2023Ownership: 0.139%Advisory Services Network LLCSold 249 shares on 5/17/2023Ownership: 0.000%View All Institutional Transactions ARGX Stock - Frequently Asked Questions Should I buy or sell argenx stock right now? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 hold rating and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARGX shares. View ARGX analyst ratings or view top-rated stocks. What is argenx's stock price forecast for 2023? 19 Wall Street analysts have issued 12 month price targets for argenx's shares. Their ARGX share price forecasts range from $425.00 to $494.00. On average, they anticipate the company's stock price to reach $455.67 in the next year. This suggests a possible upside of 17.1% from the stock's current price. View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts. How have ARGX shares performed in 2023? argenx's stock was trading at $378.83 at the beginning of 2023. Since then, ARGX shares have increased by 2.7% and is now trading at $389.10. View the best growth stocks for 2023 here. Are investors shorting argenx? argenx saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,100,000 shares, an increase of 23.0% from the April 30th total of 894,500 shares. Based on an average daily volume of 243,000 shares, the short-interest ratio is currently 4.5 days. View argenx's Short Interest. When is argenx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our ARGX earnings forecast. How were argenx's earnings last quarter? argenx SE (NASDAQ:ARGX) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($2.34) by $1.82. The firm earned $229.76 million during the quarter, compared to the consensus estimate of $191.24 million. argenx had a negative trailing twelve-month return on equity of 35.36% and a negative net margin of 79.45%. What ETFs hold argenx's stock? ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH), Loncar Cancer Immunotherapy ETF (CNCR), American CenturyFocused Dynamic Growth ETF (FDG), AdvisorShares Dorsey Wright ADR ETF (AADR), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Nasdaq Biotechnology ETF (IBBQ) and Invesco NASDAQ Next Gen 100 ETF (QQQJ). What other stocks do shareholders of argenx own? Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT). When did argenx IPO? (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is argenx's stock symbol? argenx trades on the NASDAQ under the ticker symbol "ARGX." Who are argenx's major shareholders? argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.40%), Price T Rowe Associates Inc. MD (6.87%), Artisan Partners Limited Partnership (5.45%), Avoro Capital Advisors LLC (2.31%), Jennison Associates LLC (2.04%) and BlackRock Inc. (1.20%). How do I buy shares of argenx? Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is argenx's stock price today? One share of ARGX stock can currently be purchased for approximately $389.10. How much money does argenx make? argenx (NASDAQ:ARGX) has a market capitalization of $21.67 billion and generates $445.27 million in revenue each year. The company earns $-709,590,000.00 in net income (profit) each year or ($9.29) on an earnings per share basis. How many employees does argenx have? The company employs 650 workers across the globe. How can I contact argenx? argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com. This page (NASDAQ:ARGX) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenx SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.